Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 496

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 496
---
 January 1, 2022    | ​ | ​ | ​                  | $ |  4,594,820 | ​ | ​ | ​ | ​                   | $ |        — | ​ | ​ |
| Change in fair value             | ​ | ​ | ​                  | ​ | -4,176,574 | ​ | ​ | ​ | ​                   | ​ |        — | ​ | ​ |
| Fair value at December 31, 2022  | ​ | ​ | ​                  | ​ |    418,246 | ​ | ​ | ​ | ​                   | ​ |        — | ​ | ​ |
| Issuance of derivative liability | ​ | ​ | ​                  | ​ |          — | ​ | ​ | ​ | ​                   | ​ |  104,428 | ​ | ​ |
| Change in fair value             | ​ | ​ | ​                  | ​ |   -249,492 | ​ | ​ | ​ | ​                   | ​ | -102,226 | ​ | ​ |
| Fair value at December 31, 2023  | ​ | ​ | ​                  | $ |    168,754 | ​ | ​ | ​ | ​                   | $ |    2,202 | ​ | ​ |

NOTE 12. SUBSEQUENT EVENTS The Company has evaluated all events that occurred through the date of this filing. On January 5, 2024, the Company obtained additional advances under the Liminatus unsecured promissory note totaling $700,000, which resulted in a total outstanding principal balance of $1,518,500. On February 28, 2024, the Liminatus unsecured promissory note was amended and restated to increase the aggregate principal amount to up to $2,500,000, and add advances that occurred under the note. On March 5, 2024, Iris Acquisition Corp (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has failed to comply with Nasdaq Listing Rule IM-5101-2, which requires that a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement. Pursuant to the Notice, unless the Company timely requests a hearing before The Nasdaq Hearings Panel (the “Panel”), the Company’s securities will be subject to suspension and delisting from